Colistimethate Sodium Pdr for Soln for Injection 2 million IU Malta - English - Medicines Authority

colistimethate sodium pdr for soln for injection 2 million iu

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - colistimethate sodium - powder for solution for injection - colistimethate sodium 2 million iu - antibacterials for systemic use

Colistimethate sodium 1 million IU Powder for nebuliser solution Ireland - English - HPRA (Health Products Regulatory Authority)

colistimethate sodium 1 million iu powder for nebuliser solution

noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin

Colistimethate sodium 2 million IU Powder for nebuliser solution Ireland - English - HPRA (Health Products Regulatory Authority)

colistimethate sodium 2 million iu powder for nebuliser solution

noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin

Colistimethate sodium 1 million IU Powder for solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

colistimethate sodium 1 million iu powder for solution for injection/infusion

noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin

Colistimethate sodium 2 million IU Powder for solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

colistimethate sodium 2 million iu powder for solution for injection/infusion

noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin

COLISTIMETHATE injection, powder, lyophilized, for solution United States - English - NLM (National Library of Medicine)

colistimethate injection, powder, lyophilized, for solution

xgen pharmaceuticals djb, inc. - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml - colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae , and pseudomonas aeruginosa. colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection and other antibacterial drugs, colistimethate for in